

**Title:**  
**Secondary sclerosing cholangitis induced by systemic chemotherapy**

**Authors:**  
Ángela Antón Rodríguez, Aitor Odriozola Herrán, Víctor José Echavarría Rodríguez, Sara Alonso Fernández

DOI: 10.17235/reed.2023.9653/2023

Link: [PubMed \(Epub ahead of print\)](#)

Please cite this article as:

Antón Rodríguez Ángela, Odriozola Herrán Aitor, Echavarría Rodríguez Víctor José, Alonso Fernández Sara.  
Secondary sclerosing cholangitis induced by systemic chemotherapy. Rev Esp Enferm Dig 2023. doi:  
10.17235/reed.2023.9653/2023.

*This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.*

CC 9653 inglés

## Secondary sclerosing cholangitis induced by systemic chemotherapy

Ángela Antón Rodríguez, Aitor Odriozola Herrán, Víctor José Echavarría Rodríguez, Sara Alonso Fernández

Gastroenterology and Hepatology Department. Clinical and Translational Research in Digestive Diseases. Valdecilla Research Institute (IDIVAL). Hospital Universitario Marqués de Valdecilla. Santander, Spain

**Correspondence:** Ángela Antón Rodríguez

e-mail: antonrodriguezangela@gmail.com

*Conflict of interest: the authors declare no conflict of interest.*

**Keywords:** Sclerosing cholangitis. Chemotherapy.

*Dear Editor,*

There are multiple causes of secondary sclerosing cholangitis (SSC), including mechanical obstruction, ischemia, congenital abnormalities, cholangiopathy of the critically ill patient and rarely, chemotherapy (1,2).

### CASE REPORT

We present the case of a 52-year-old female with a history of left breast invasive ductal carcinoma treated with neoadjuvant chemotherapy (adriamycin, cyclophosphamide and paclitaxel), surgery and radiotherapy in March 2021.

She was admitted in July 2022 due to painless jaundice and pruritus with marked serum cholestasis. Magnetic resonance cholangiopancreatography showed multiple strictures and dilatations involving the intra and extrahepatic bile ducts (Fig. 1A),

without any extrinsic stenotic cause. Findings were confirmed by endoscopic retrograde cholangiopancreatography (ERCP) with cholangioscopy (Fig. 1B). Biopsies were negative for malignancy and IgG4 disease. In addition, autoantibodies were negative and serum IgG4 levels were normal. Due to these findings and the history of recent chemotherapy, the patient was diagnosed with paclitaxel-induced sclerosing cholangitis, initiating treatment with ursodeoxycholic acid.

Over the following two months, she suffered two episodes of *Klebsiella pneumoniae* bacteremia due to acute cholangitis. Dilatation and placement of plastic stents in both biliary trees were performed and prophylactic antibiotherapy was started. The patient had a poor evolution and was not a candidate for liver transplantation on account of a recent neoplasia. She died six months later due to sepsis secondary to multiple hepatic abscesses.

## Discussion

Chemotherapy-induced SSC is a form of SSC occasionally described after hepatic transarterial chemotherapy (fluoropyridines). However, cases triggered by systemic chemotherapy are anecdotal, with five cases reported in the literature, some of them associated with taxanes (3,4), four of them in Japan.

The pathogenic mechanism is unknown, probably induced by direct toxicity with ischemic changes in the peribiliary vascular plexuses. Treatment includes ursodeoxycholic acid, biliary drainage and suspension of chemotherapy. It has a poor prognosis because of the rapid deterioration of liver function and the underlying neoplastic disease (3).

## References

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol 2022;77(3):761-806. DOI: 10.1016/j.jhep.2022.05.011
2. Imam MH, Talwalkar JA, Lindor KD. Secondary sclerosing cholangitis: pathogenesis, diagnosis, and management. Clin Liver Dis 2013;17(2):269-77. DOI: 10.1016/j.cld.2012.11.004

3. Kusakabe A, Ohkawa K, Fukutake N, et al. Chemotherapy-induced sclerosing cholangitis caused by systemic chemotherapy. ACG Case Rep J 2019;6(7):e00136. DOI: 10.14309/crj.0000000000000013
4. Matsuo T, Nakamura Y, Suzuki K. A case of secondary sclerosing cholangitis caused by chemotherapy with nab-paclitaxel. Nihon Shokakibyo Gakkai Zasshi 2015;112(5):888-95. DOI: 10.11405/nisshoshi.112.888




Fig. 1. A. Endoscopic retrograde cholangiopancreatography (ERCP) with cholangioscopy showing multiple strictures and dilations. B. Magnetic resonance (MR) cholangiopancreatography with the same findings.